Immunovant (NASDAQ:IMVT) CTO Jay Stout Sells 2,595 Shares of Company Stock

Posted by Geri Gentry on Oct 24th, 2026

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) CTO Jay Stout sold 2,595 shares of the company’s stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $28.94, for a total value of $75,099.30. Following the transaction, the chief technology officer directly owned 198,937 shares in the company, valued at approximately $5,757,236.78. This trade represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Immunovant Stock Performance

Shares of NASDAQ:IMVT opened at $28.41 on Friday. Immunovant, Inc. has a 52-week low of $18.74 and a 52-week high of $45.42. The business’s 50 day simple moving average is $35.98 and its two-hundred day simple moving average is $34.70. The firm has a market cap of $5.87 billion, a P/E ratio of -10.07 and a beta of 0.84.

Immunovant (NASDAQ:IMVT – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.12). The firm had revenue of $7.09 million during the quarter, compared to analysts’ expectations of $7.09 million. During the same period last year, the company posted ($0.71) EPS. On average, equities analysts forecast that Immunovant, Inc. will post -2.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IMVT. Sterling Capital Management LLC lifted its stake in Immunovant by 856.0% during the 3rd quarter. Sterling Capital Management LLC now owns 2,868 shares of the company’s stock valued at $97,000 after acquiring an additional 2,568 shares in the last quarter. Inspire Investing LLC bought a new stake in shares of Immunovant in the 3rd quarter worth $413,000. GAMMA Investing LLC grew its stake in shares of Immunovant by 63.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,224 shares of the company’s stock worth $41,000 after acquiring an additional 476 shares in the last quarter. Two Seas Capital LP raised its holdings in shares of Immunovant by 46.5% in the third quarter. Two Seas Capital LP now owns 4,612,692 shares of the company’s stock valued at $155,817,000 after purchasing an additional 1,464,187 shares during the last quarter. Finally, Engineers Gate Manager LP raised its holdings in shares of Immunovant by 179.7% in the second quarter. Engineers Gate Manager LP now owns 24,220 shares of the company’s stock valued at $933,000 after purchasing an additional 15,560 shares during the last quarter. Institutional investors own 47.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on IMVT shares. HC Wainwright restated a “buy” rating on shares of Immunovant in a report on Thursday, September 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunovant in a research note on Tuesday, August 25th. JPMorgan Chase & Co. lifted their price objective on shares of Immunovant from $47.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Citigroup reissued a “positive” rating on shares of Immunovant in a research report on Thursday, September 24th. Finally, Sanford C. Bernstein raised shares of Immunovant to a “hold” rating in a research report on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Get Our Latest Analysis on IMVT

About Immunovant

(Get Free Report)

Immunovant, Inc (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company developing medicines for autoimmune diseases. The company focuses on conditions in which disease-causing immunoglobulin G (IgG) antibodies contribute to tissue damage and other symptoms.

Immunovant’s lead product candidate is batoclimab, also known as IMVT-1401, a fully human monoclonal antibody designed to inhibit the neonatal Fc receptor (FcRn). By reducing the circulation of pathogenic IgG antibodies, batoclimab is being evaluated as a potential treatment for autoimmune disorders, including generalized myasthenia gravis, thyroid eye disease and chronic inflammatory demyelinating polyneuropathy.